

## Product datasheet for **TL506307V**

### Lpcat1 Mouse shRNA Lentiviral Particle (Locus ID 210992)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Lpcat1 Mouse shRNA Lentiviral Particle (Locus ID 210992)
Locus ID:	210992
Synonyms:	2900035H07Rik; Ayt12; BB137372; BC005662; C87117; LPCAT; rd11
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	Ayt12 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">BC066809</a> , <a href="#">NM_145376</a> , <a href="#">NM_145376.1</a> , <a href="#">NM_145376.2</a> , <a href="#">NM_145376.3</a> , <a href="#">NM_145376.4</a> , <a href="#">NM_145376.5</a> , <a href="#">BC005662</a> , <a href="#">NM_001368681</a> , <a href="#">NM_001368682</a> , <a href="#">NM_145376.6</a>
UniProt ID:	<a href="#">Q3TFD2</a>
Summary:	Possesses both acyltransferase and acetyltransferase activities (PubMed:16704971). Activity is calcium-independent (PubMed:18285344). Mediates the conversion of 1-acyl-sn-glycero-3-phosphocholine (LPC) into phosphatidylcholine (PC) (PubMed:16704971, PubMed:18156367). Displays a clear preference for saturated fatty acyl-CoAs, and 1-myristoyl or 1-palmitoyl LPC as acyl donors and acceptors, respectively (PubMed:16704971, PubMed:18285344). May synthesize phosphatidylcholine in pulmonary surfactant, thereby playing a pivotal role in respiratory physiology (PubMed:16704971). Involved in the regulation of lipid droplet number and size (By similarity).[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).